Minglei Zhuo, Hanxiao Chen, Tianzhuo Zh, Zhao J et al. The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. 2018;共同通讯作者,Cancer Biomarkers,vol. 22, no. 3, pp. 467-476,

Zhong J, Guo Z, Zhao J, et al. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.,THORACIC CANCER,(11):2088-2095

Yang X, Zhuo M, Zhao J, et al. Optimal first-line treatment for advanced thymic carcinoma. Thorac Cancer. 2019 Nov;10(11):2081-2087.,THORACIC CANCER,(11):2081-2087.

Wang S, Chen H, Zhao J, et al. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.,lung cancer,135:116-122.

Zhao J, Lin G, Zhuo M, et al. Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.,lung cancer,141:114-118

Zhuo M, Guan Y, Yang X ,Zhao J *et al. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.,Clin Cancer Res,26(4):892-901

Xue Yang , Chuan Huang , Rongrong Chen , Jun Zhao * Resolving Resistance to Osimertinib Therapy using Afatinib in a NSCLC Patient with an EGFR L718Q Mutation.,Clinical lung cancer,

基于外周血分子分型的肺癌个体化诊疗体系建立及临床推广应用, 科技进步奖, 第4完成人 , 教育部, 2019.1

肺癌分子靶向治疗耐药机制探索

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式
2021	肿瘤内科学	硕士	专业学位	临床技能训练与研究	全国统考